Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

Author(s):
Kelderman, S.; Heemskerk, B.; Tinteren, H. van; Brom, R.R.H. van den; Hospers, G.A.P.; Eertwegh, A.J.M. van den; Kapiteijn, E.W.; Groot, J.W.B. de; Soetekouw, P.; Jansen, R.L.; Fiets, E.; Furness, A.J.S.; Renn, A.; Krzystanek, M.; Szallasi, Z.; Lorigan, P.; Gore, M.E.; Schumacher, T.N.M.; Haanen, J.B.A.G.; Larkin, J.M.G.; Blank, C.U.
Published
2014
Publication type
Article / Letter to editor
MelanomaImmunotherapyIpilimumabLactate dehydrogenaseBiomarker
Date issued
2014-05-31
Language
English
Is part of
Cancer Immunology, Immunotherapy (2014), Vol. 63, no. 5, p. 449-458
hdl
1887/104585
doi
10.1007/s00262-014-1528-9